ArticleOncoTargets and therapy2017
Overall survival in renal cell carcinoma after introduction of targeted therapies: a Norwegian population-based study.
Article in OncoTargets and therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Primary renal parenchymal squamous cell carcinoma mimicking abscess: value of trans-urinary tract fine-needle aspiration in preoperative evaluation: a case report and literature review.Medical molecular morphology · 2026Review
- Overall Survival of Patients with Metastatic Renal Cell Carcinoma Following the Introduction of Targeted and Immunotherapies: A Norwegian Retrospective, Real-World Registry Data Study (RECON3).Cancer management and research · 2025Article
- Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial.The oncologist · 2024Article
- Surgical management of renal cancer metastasis in the humerus: novel use of a trabecular metal spacer.BMJ case reports · 2022Article
- Association of Health-Related Quality of Life with Overall Survival in Older Americans with Kidney Cancer: A Population-Based Cohort Study.Healthcare (Basel, Switzerland) · 2021Article
- Nephrectomy improves the survival of metastatic renal cell cancer patients with moderate to good performance status-results from a Finnish nation-wide population-based study from 2005 to 2010.World journal of surgical oncology · 2021Article
- Prognostic Value of Plasma hPGCancers · 2021Article
- Transition to Targeted Therapies Improved the Prognosis and Increased the Utilization of Medical Treatments among Patients with Synchronous Metastatic Renal Cell Cancer.International journal of surgical oncology · 2021Article
- Article
- The Association Between Small Primary Tumor Size and Prognosis in Metastatic Renal Cell Carcinoma: Insights from Two Independent Cohorts of Patients Who Underwent Cytoreductive Nephrectomy.European urology oncology · 2020Article
- Using Data from a Sickness Fund Claims Database to Assess the Treatment Patterns and Healthcare Resource Utilization among Patients with Metastatic Renal Cell Carcinoma in Germany.Urologia internationalis · 2020Observational
- Real-world treatment patterns and adverse events in metastatic renal cell carcinoma from a large US claims database.BMC cancer · 2019Article
- Real-world cost-effectiveness of targeted therapy in metastatic renal cell carcinoma in Sweden: a population-based retrospective analysis.Cancer management and research · 2019Article
- Article
- Biomarkers defining probability of receiving second-line targeted therapy in metastatic renal cell carcinoma.Medical oncology (Northwood, London, England) · 2018Article
- Utilization and efficacy of second-line targeted therapy in metastatic renal cell carcinoma: data from a national registry.BMC cancer · 2017Article
- Eligibility for phase 3 clinical trials of systemic therapy in real-world patients with metastatic renal cell cancer managed in a rural region.Medical oncology (Northwood, London, England) · 2017Article
- Observational study on the evolution of systemic treatments for advanced renal cell carcinoma in Southwest Finland between 2010 and 2021.Therapeutic advances in urologyArticle
- Factors Associated With Prescription of Systemic Therapy in Real-world Patients With Metastatic Renal Cell Cancer Managed in a Rural Region.Cancer diagnosis & prognosisArticle
- Management of Patients With Metastatic Renal Cell Cancer and Bone Metastases.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis population-wide retrospective, non-interventional registry study assessed changes in overall survival (OS) and factors influencing OS in Norwegian patients with renal cell carcinoma (RCC).
methodsTwo population-wide health registries were used to identify all RCC patients with (mRCC) or without metastases diagnosed before (2002-2005) and after (2006-2008 and 2009-2011) introduction of targeted therapies. Median OS was estimated using Kaplan-Meier method. Cox proportional hazards regression modeling was used to identify prognostic factors.
resultsOverall, 5,463 patients were diagnosed with RCC during 2002-2005 (n=1,898), 2006-2008 (n=1,631), and 2009-2011 (n=1,934); of these, 1,678 (31%) had mRCC. Patients diagnosed in 2009-2011 and 2006-2008 had significant (
conclusionOS increased in RCC and mRCC patients in Norway between 2002 and 2011 following introduction of targeted therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.